Australian and ACT Communicable Diseases Data (Crude Rate)
Sourced from the National Notifiable Diseases Surveillance System (NNDSS) at the Australian Government Department of Health
Note: Empty cells indicate that the condition may not have been notifiable during the period

The data is presented by the ACT Government for the purpose of disseminating information for the benefit of the public. The ACT Government has taken great care to ensure the information in this report is as correct and accurate as possible. Whilst the information is considered to be true and correct at the date of publication, changes in circumstances after the time of publication may impact on the accuracy of the information. Differences in statistical methods and calculations, data updates and guidelines may result in the information contained in this report varying from previously published information.

Australian and ACT Communicable Diseases Data (Crude Rate)
Sourced from the National Notifiable Diseases Surveillance System (NNDSS) at the Australian Government Department of Health
Note: Empty cells indicate that the condition may not have been notifiable during the period

The data is presented by the ACT Government for the purpose of disseminating information for the benefit of the public. The ACT Government has taken great care to ensure the information in this report is as correct and accurate as possible. Whilst the information is considered to be true and correct at the date of publication, changes in circumstances after the time of publication may impact on the accuracy of the information. Differences in statistical methods and calculations, data updates and guidelines may result in the information contained in this report varying from previously published information.

* = Estimate has a relative standard error of 25% to 50% and should be used with caution.
** = Estimate has a high level of sampling error (relative standard error of 51% to 90%), meaning that it is unsuitable for most uses.
Please note that the number of cases may vary between indicators as "Not Stated" records have been excluded


Robsons Classification:
Group 01 = Spontaneous single cephalic nulliparous 37 or more weeks gestation.
Group 02 = Induced or no labour, single cephalic nulliparous 37 or more weeks gestation.
Group 02a = Induced, single cephalic nulliparous 37 or more weeks gestation.
Group 02b = No labour, single cephalic nulliparous 37 or more weeks gestation.
Group 03 = Spontaneous single cephalic multiparous 37 or more weeks, no previous caesarean section.
Group 04 = Induced or no labour single cephalic multiparous 37 or more weeks, no previous caesarean section.
Group 04a = Induced, single cephalic multiparous 37 or more weeks, no previous caesarean section.
Group 04b = No labour, single cephalic multiparous 37 or more weeks, no previous caesarean section.
Group 05 = All single cephalic multiparous 37 or more weeks with a previous caesarean section.
Group 06 = All nulliparous women with a single breech pregnancy.
Group 07 = All multiparous women with a single breech pregnancy, with or without previous caesarean section.
Group 08 = All women with a multiple pregnancy, with or without previous caesarean section.
Group 09 = All women with a single pregnancy with transverse or oblique lie, with or without previous caesarean section.
Group 10 = All women with a single cephalic pregnancy at less than 37 weeks gestation.


The data is presented by the ACT Government for the purpose of disseminating information for the benefit of the public. The ACT Government has taken great care to ensure the information in this report is as correct and accurate as possible. Whilst the information is considered to be true and correct at the date of publication, changes in circumstances after the time of publication may impact on the accuracy of the information. Differences in statistical methods and calculations, data updates and guidelines may result in the information contained in this report varying from previously published information.

ACT Selected Cancer incidence and mortality

The data is presented by the ACT Government for the purpose of disseminating information for the benefit of the public. The ACT Government has taken great care to ensure the information in this report is as correct and accurate as possible. Whilst the information is considered to be true and correct at the date of publication, changes in circumstances after the time of publication may impact on the accuracy of the information. Differences in statistical methods and calculations, data updates and guidelines may result in the information contained in this report varying from previously published information.

Proportion (%) of overweight or obese young people aged 18–24 years, ACT and
Australia, 2007–08, 2011–12 and 2014–15.

Source: ABS, National Health Survey, 2007–15

Data from the Australian Bureau of Statistics National Aboriginal and Torres Strait Islander Health Survey

Aboriginal and Torres Strait Islander population projections

The data is presented by the ACT Government for the purpose of disseminating information for the benefit of the public. The ACT Government has taken great care to ensure the information in this report is as correct and accurate as possible. Whilst the information is considered to be true and correct at the date of publication, changes in circumstances after the time of publication may impact on the accuracy of the information. Differences in statistical methods and calculations, data updates and guidelines may result in the information contained in this report varying from previously published information.

National Drugs Strategy Household Survey (NDSHS)
* Estimate has a relative standard error of 25% to 50% and should be used with caution.
** Estimate has a high level of sampling error (relative standard error of 51% to 90%), meaning that it is unsuitable for most uses.
# Statistically significant change between 2016 and 2019.
n.p. not published because of small numbers, confidentiality or other concerns about the quality of the data.
(a) Used at least 1 of 16 classes of illicit drugs in the previous 12 months in 2019. The number and type of illicit drug used varied over time.
(aa) Used the specified drug in the previous 12 months.
(ab) Used in the previous 12 months.
(ac) Used in the previous 12 months for non medical purposes.
(b) State results do not include data from the 8 Indigenous remote communities interviewed in the NT in 2019. These data are included in national estimates.
(bb) Excludes over-the-counter medications such as paracetamol and aspirin.
(c) Includes people who reported smoking daily, weekly or less than weekly.
(d) Consumed an alcoholic drink in the previous 12 months.
(e) For non-medical purposes.
(f) Illicit use of at least 1 of 12 classes of drugs (excluding pharmaceuticals) in the previous 12 months in 2019. The number and type of drug used varied over time.
(g) Excludes over-the-counter medications such as paracetamol and aspirin.
(h) Includes use of heroin, non-medical use of pain-killers/pain-relievers and opioids or non-medical use of methadone/buprenorphine.
(i) Used at least 1 of 16 classes of illicit drugs in the previous 12 months in 2019. The number and type of illicit drug used varied over time.
Notes
1. Smoking status in 2010 has been revised. Trend data may not match previously published results.
2. The calculation of drinking status and alcohol risk variables was updated for all years in 2019. Trend data may not match previously published results.
3. In 2016, pain-killer/pain-relievers and opioids sections were combined into one section and references and questions about use of non-opioid over-the-counter drugs such as paracetamol and aspirin were removed. Data are not considered comparable to previous survey waves.
4. The NDSHS offers introductory text for each class of drug, including examples of the drugs included. Examples for hallucinogens, inhalants and New and Emerging Psychoactive Substances were changed in 2019, which may have impacted trend results since 2016.
5. State results do not include data from the 8 Indigenous remote communities interviewed in the NT in 2019. These data are included in national estimates.
6. Age-standardisation has been revised in 2019. Trend data may not match previously published results.
Source: NDSHS 2019

National Drugs Strategy Household Survey (NDSHS)
* Estimate has a relative standard error of 25% to 50% and should be used with caution.
** Estimate has a high level of sampling error (relative standard error of 51% to 90%), meaning that it is unsuitable for most uses.
# Statistically significant change between 2016 and 2019.
n.p. not published because of small numbers, confidentiality or other concerns about the quality of the data.
(a) Used at least 1 of 16 classes of illicit drugs in the previous 12 months in 2019. The number and type of illicit drug used varied over time.
(aa) Used the specified drug in the previous 12 months.
(ab) Used in the previous 12 months.
(ac) Used in the previous 12 months for non medical purposes.
(b) State results do not include data from the 8 Indigenous remote communities interviewed in the NT in 2019. These data are included in national estimates.
(bb) Excludes over-the-counter medications such as paracetamol and aspirin.
(c) Includes people who reported smoking daily, weekly or less than weekly.
(d) Consumed an alcoholic drink in the previous 12 months.
(e) For non-medical purposes.
(f) Illicit use of at least 1 of 12 classes of drugs (excluding pharmaceuticals) in the previous 12 months in 2019. The number and type of drug used varied over time.
(g) Excludes over-the-counter medications such as paracetamol and aspirin.
(h) Includes use of heroin, non-medical use of pain-killers/pain-relievers and opioids or non-medical use of methadone/buprenorphine.
(i) Used at least 1 of 16 classes of illicit drugs in the previous 12 months in 2019. The number and type of illicit drug used varied over time.
Notes
1. Smoking status in 2010 has been revised. Trend data may not match previously published results.
2. The calculation of drinking status and alcohol risk variables was updated for all years in 2019. Trend data may not match previously published results.
3. In 2016, pain-killer/pain-relievers and opioids sections were combined into one section and references and questions about use of non-opioid over-the-counter drugs such as paracetamol and aspirin were removed. Data are not considered comparable to previous survey waves.
4. The NDSHS offers introductory text for each class of drug, including examples of the drugs included. Examples for hallucinogens, inhalants and New and Emerging Psychoactive Substances were changed in 2019, which may have impacted trend results since 2016.
5. State results do not include data from the 8 Indigenous remote communities interviewed in the NT in 2019. These data are included in national estimates.
6. Age-standardisation has been revised in 2019. Trend data may not match previously published results.
Source: NDSHS 2019

Data from the Australian Bureau of Statistics National Aboriginal and Torres Strait Islander Health Survey